# Nuwellis, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Nuwellis, Inc.). ## Overview Nuwellis, Inc. is a U.S.-based medical technology company focused on the Aquadex System, an ultrafiltration platform used to remove excess fluid from patients. Its business combines console systems, disposable blood filters and catheters, and related clinical support for hospitals and clinics, with sales centered in the United States and selected international markets. ## Products & services • Aquadex ultrafiltration console systems • Disposable blood filters and catheters • Clinical training and technical support • Pediatric fluid-management therapy applications • Product enhancements and software upgrades - **Aquadex console systems** (20%) — Capital equipment used to deliver ultrafiltration therapy in hospital settings. - **Disposable circuits and blood sets** (60%) — Single-use blood filters and catheters used with Aquadex consoles. - **Technical services and support** (10%) — Training, implementation, and clinical support provided to hospital customers. - **International distributor sales** (5%) — Sales outside the U.S. through specialty distributors in selected markets. - **Other product and development-related revenue** (5%) — Other device-related sales and commercial activity tied to the Aquadex platform. - Aquadex ultrafiltration console systems - Disposable blood filters and catheters - Clinical training and technical support - Pediatric fluid-management therapy applications - Product enhancements and software upgrades ## Customers Nuwellis sells primarily to hospitals, health systems, and academic medical centers that treat fluid overload in complex patients. Its core users include cardiac surgery, heart failure, critical care, and pediatric programs that need controlled fluid removal and clinical support around therapy delivery. - **U.S. hospitals and health systems** (primary) — Buy Aquadex consoles, disposables, and support for inpatient fluid management programs. - **Academic medical centers** (primary) — Use the system in advanced heart failure and critical care protocols where clinical evidence matters. - **Cardiac surgery programs** (secondary) — Use ultrafiltration around post-cardiac surgery fluid management and recovery. - **Pediatric hospitals** (secondary) — Adopt the pediatric-cleared system for children needing kidney replacement or fluid therapy. - **International specialty distributors** (secondary) — Purchase products for resale to hospitals and clinics in their local markets. - Hospitals and health systems treating fluid-overloaded patients - Academic medical centers with advanced heart failure programs - Critical care units needing controlled fluid management - Cardiac surgery programs using ultrafiltration post-procedure - Pediatric hospitals treating patients over 20 kg ## Geography Nuwellis is centered in the United States, where it sells through a direct salesforce and has ten sales territories. It also serves selected foreign jurisdictions through independent specialty distributors, but the company has stated that its focus is the U.S. market and a small set of retained international markets. - **United States** (85%) — Primary market and direct-sales focus - **Selected international markets** (15%) — Residual foreign jurisdictions and distributor-led sales - United States is the core commercial market - Direct salesforce covers ten U.S. sales territories - International sales run through specialty distributors - Retained foreign jurisdictions include Singapore, Hong Kong, Israel, and Brazil - Geographic focus affects service, regulatory, and distribution needs ## Strategy Nuwellis is prioritizing commercial investment in U.S. cardiac surgery, pediatric, and hospital-based outpatient opportunities where it sees the strongest clinical demand. It is also extending the Aquadex platform through software upgrades and product enhancements, while evaluating adjacent renal-monitoring technologies that could broaden its care platform. - **Concentrate on the U.S. market** (short-term) — The company believes U.S. demand offers the strongest near-term commercial opportunity and supportability. - **Expand pediatric and cardiac surgery adoption** (medium-term) — These clinical settings can increase utilization of the Aquadex platform and deepen hospital relationships. - **Improve product performance and user experience** (medium-term) — Device enhancements can support customer satisfaction, retention, and broader clinical use. - **Broaden the platform beyond ultrafiltration** (long-term) — Adjacent monitoring technologies could extend the company’s role in cardiorenal care. - Focus commercial resources on the U.S. market - Expand adoption in cardiac surgery and pediatric programs - Grow hospital-based outpatient fluid-management use cases - Release software upgrades to improve device performance - Evaluate adjacent renal-monitoring technologies ## Risks Nuwellis depends on a concentrated customer base, third-party manufacturing, and continued access to capital, so disruptions in any of these areas could materially affect operations. As a medical device company, it also faces regulatory, clinical adoption, reimbursement, and product-performance risks that can slow commercialization or limit utilization. - **Capital funding risk** [critical] — The company expects to need additional capital to support operations and strategic initiatives. - **Customer concentration** [high] — A limited number of customers account for a large share of revenue, so loss or reduced ordering can materially hurt sales. - **Third-party manufacturing and supply chain** [high] — The company depends on external manufacturers and suppliers for commercial volumes and components. - **Nasdaq listing compliance** [high] — The stock has faced minimum stockholders' equity and bid-price compliance pressure. - **Clinical adoption and reimbursement** [medium] — Hospitals must adopt ultrafiltration therapy and justify use versus competing treatments. - Needs additional capital to fund operations and growth - Customer concentration can cause revenue volatility - Third-party manufacturing creates supply and quality risk - Nasdaq listing compliance remains a risk - Clinical adoption depends on physician and hospital uptake ## Accounting Revenue is recognized under ASC 606 when customers obtain control of consoles, disposables, or services, so shipment timing and customer ordering patterns can affect quarterly results. Investors should also watch estimates tied to stock-based compensation, warrant valuation, long-lived asset impairment, and income tax reserves, all of which can move reported results in a small-cap medical device company. - **Revenue recognition timing** — Quarterly comparability - **Warrant valuation** — Non-cash earnings volatility - **Long-lived asset impairment** — Potential write-downs - **Stock-based compensation** — Reported SG&A and R&D - **Income tax reserves** — Net income and balance sheet - Revenue recognition depends on control transfer under ASC 606 - Quarterly sales can swing with customer ordering patterns - Warrant accounting can create fair-value remeasurement volatility - Long-lived asset impairment estimates may affect carrying values - Stock-based compensation and tax reserves rely on management estimates --- *Last updated: 2026-04-29T04:42:17.507733+00:00*